Analyst firms · Morgan Stanley · JNJ
Morgan Stanley JNJ price target and rating history
Johnson & Johnson (JNJ) · Health Care
Morgan Stanley rates Johnson & Johnson (JNJ) Overweight with a $262 price target, as of its latest action on Jan 28, 2026. It has published 4 rating actions on JNJ since September 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a JNJ price target in the last 12 months, the median target is $263.50. Morgan Stanley's $262 is 1% below that.
- Current rating
- Overweight
- Price target
- $262
- Median target, all firms
- $263.50
- Actions on JNJ
- 4
Morgan Stanley price target on JNJ
Every Morgan Stanley rating on JNJ
- Jan 28, 2026
- Apr 6, 2022
- Jan 24, 2022
- Sep 7, 2021
How other firms rate JNJ
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Erste Group | Hold | Oct 21, 2026 | |
| UBS | Buy | $320 | Sep 2, 2026 |
| Leerink Partners | Outperform | $265 | May 13, 2026 |
| TD Cowen | Buy | $250 | Apr 8, 2026 |
| Morgan Stanley | Overweight | $262 | Jan 28, 2026 |
Questions about Morgan Stanley and JNJ
- What is Morgan Stanley's price target for JNJ?
- Morgan Stanley's latest stated price target for Johnson & Johnson (JNJ) is $262, from its action on Jan 28, 2026.
- What is Morgan Stanley's rating on JNJ?
- Morgan Stanley rates JNJ Overweight, a bullish rating, as of Jan 28, 2026.
- When did Morgan Stanley last change its view on JNJ?
- On Jan 28, 2026, Morgan Stanley upgrades to Overweight from Equal-Weight, price target $262.
- How does Morgan Stanley's JNJ target compare with other analysts?
- Across 4 firms with a JNJ price target in the last 12 months, the median target is $263.50. Morgan Stanley's $262 is 1% below that.
More JNJ rating histories
All Morgan Stanley ratingsJNJ news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.